Benzinga | Mar 29, 2021 07:32AM EDT

Biohaven Enrolls First Patient in Phase 2/3 Trial Of Oral Zavegepant, Prompting $100M Milestone Funding Payment Fom Royalty Pharma

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that it has enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine.